Trial Profile

A Multicenter, Randomized Open-Label Study to Assess the Efficacy, Safety, and Pharmacokinetics of Upadacitinib With a Tocilizumab Reference Arm in Subjects From 1 Year to Less Than 18 Years Old With Active Systemic Juvenile Idiopathic Arthritis

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tocilizumab (Primary) ; Tocilizumab (Primary) ; Upadacitinib (Primary)
Indications Juvenile rheumatoid arthritis
Focus Adverse reactions; Registrational; Therapeutic Use
Acronyms SELECT-sJIA
Sponsors AbbVie

13 Jan 2025 Planned End Date changed from 19 Jun 2029 to 1 Jun 2029.
13 Jan 2025 Planned primary completion date changed from 28 Feb 2027 to 1 Jun 2029.
30 Apr 2024 Planned End Date changed from 30 Oct 2030 to 19 Jun 2029.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com